Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALDOSE-1: Vidofludimus calcium for induction and maintenance therapy in moderate-to-severe ulcerative colitis
2017-003703-22Phase 2Unknown
- Sponsor
- Immunic Therapeutics
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vidofludimus calcium in autoimmune colitis (4 arms), sponsored by Immunic Therapeutics. Primary endpoint: Symptomatic remission and endoscopic healing at induction. Status: unknown.
02
Drugs
vidofludimus calcium
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2017-003703-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003703-22.